Table of Content


Introduction
Executive Summary
Acute Ischemic Stroke: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Acute Ischemic Stroke – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Acute Ischemic Stroke companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acute Ischemic Stroke Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Nerinetide: NoNO
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Mid Stage Products (Phase II)
• Comparative Analysis
SP-8203: Shin Poong Pharmaceutical
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early stage products (Phase I/II)
• Comparative Analysis
JTR 161: Teijin Pharma Limited
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
• Comparative Analysis
Acute Ischemic Stroke Key Companies
Acute Ischemic Stroke Key Products
Acute Ischemic Stroke- Unmet Needs
Acute Ischemic Stroke- Market Drivers and Barriers
Acute Ischemic Stroke- Future Perspectives and Conclusion
Acute Ischemic Stroke Analyst Views
Acute Ischemic Stroke Key Companies
Appendix



List of Figures



Figure 1 Total Products for Acute Ischemic Stroke
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables



Table 1 Total Products for Acute Ischemic Stroke
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products